{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:53:40Z","timestamp":1792630420456,"version":"4.5.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T00:00:00Z","timestamp":1723680000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic &amp; Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.bmcl.2024.129930","type":"journal-article","created":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T23:17:50Z","timestamp":1724368670000},"page":"129930","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Discovery of BI-9787, a potent zwitterionic ketohexokinase inhibitor with oral bioavailability"],"prefix":"10.1016","volume":"112","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4961-4575","authenticated-orcid":false,"given":"Niklas","family":"Heine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5832-3959","authenticated-orcid":false,"given":"Alexander","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0405-6063","authenticated-orcid":false,"given":"Alexander","family":"Pautsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Gottschling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingo","family":"Uphues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1297-0015","authenticated-orcid":false,"given":"Margit","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Ebenhoch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aniket","family":"Magarkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Nosse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5543-6387","authenticated-orcid":false,"given":"J\u00f6rg Thomas","family":"Kley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2024.129930_b0005","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1146\/annurev-nutr-062220-025831","article-title":"Dietary fructose and fructose-induced pathologies","volume":"42","author":"Jung","year":"2022","journal-title":"Annu Rev Nutr"},{"key":"10.1016\/j.bmcl.2024.129930_b0010","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1016\/j.cmet.2021.09.010","article-title":"Molecular aspects of fructose metabolism and metabolic disease","volume":"33","author":"Herman","year":"2021","journal-title":"Cell Metab"},{"key":"10.1016\/j.bmcl.2024.129930_b0015","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1080\/10408363.2019.1711360","article-title":"Fructose and hepatic insulin resistance","volume":"57","author":"Softic","year":"2020","journal-title":"Crit Rev Clin Lab Sci"},{"key":"10.1016\/j.bmcl.2024.129930_b0020","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1152\/physrev.00019.2009","article-title":"Metabolic effects of fructose and the worldwide increase in obesity","volume":"90","author":"Tappy","year":"2010","journal-title":"Physiol Rev"},{"key":"10.1016\/j.bmcl.2024.129930_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154925","article-title":"Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease","volume":"126","author":"Negi","year":"2022","journal-title":"Metabolism"},{"key":"10.1016\/j.bmcl.2024.129930_b0030","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/ejcn.2011.132","article-title":"Obesity and energy balance: is the tail wagging the dog?","volume":"65","author":"Wells","year":"2011","journal-title":"Eur J Clin Nutr"},{"key":"10.1016\/j.bmcl.2024.129930_b0035","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.coisb.2017.11.005","article-title":"New concepts in feedback regulation of glucose metabolism","volume":"8","author":"Locasale","year":"2018","journal-title":"Curr Opin Syst Biol"},{"key":"10.1016\/j.bmcl.2024.129930_b0040","doi-asserted-by":"crossref","first-page":"4479","DOI":"10.3390\/ijms21124479","article-title":"Fructose and uric acid: major mediators of cardiovascular disease risk starting at pediatric age","volume":"21","author":"Russo","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"11","key":"10.1016\/j.bmcl.2024.129930_b0045","doi-asserted-by":"crossref","first-page":"4320","DOI":"10.1073\/pnas.1119908109","article-title":"Opposing effects of fructokinase C and A isoforms on fructose-induced metabolic syndrome in mice","volume":"109","author":"Ishimoto","year":"2012","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.bmcl.2024.129930_b0050","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1172\/JCI94427","article-title":"Ketohexokinase C blockade ameliorates fructose-induced metabolic dysfunction in fructose-sensitive mice","volume":"128","author":"Lanaspa","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bmcl.2024.129930_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2019.08.100","article-title":"The RNA-binding protein A1CF regulates hepatic fructose and glycerol metabolism via alternative RNA splicing","volume":"29","author":"Nikolaou","year":"2019","journal-title":"Cell Rep"},{"key":"10.1016\/j.bmcl.2024.129930_b0060","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/s42255-020-0222-9","article-title":"The small intestine shields the liver from fructose-induced steatosis","volume":"2","author":"Jang","year":"2020","journal-title":"Nat Metabo"},{"key":"10.1016\/j.bmcl.2024.129930_b0065","article-title":"Pharmacologic inhibition of ketohexokinase prevents fructose-induced metabolic dysfunction","volume":"48","author":"Gutierrez","year":"2021","journal-title":"Mole Metab"},{"key":"10.1016\/j.bmcl.2024.129930_b0070","article-title":"Ketohexokinase inhibition improves NASH by reducing fructose-induced steatosis and fibrogenesis","volume":"3","author":"Shepherd","year":"2021","journal-title":"JHEP Rep"},{"key":"10.1016\/j.bmcl.2024.129930_b0075","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.3390\/ijms22052431","article-title":"Osthol ameliorates kidney damage and metabolic syndrome induced by a high-fat\/high-sugar diet","volume":"22","author":"Garc\u00eda-Arroyo","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bmcl.2024.129930_b0080","doi-asserted-by":"crossref","first-page":"13546","DOI":"10.1021\/acs.jmedchem.0c00944","article-title":"Discovery of PF-06835919: a potent inhibitor of ketohexokinase (KHK) for the treatment of metabolic disorders driven by the overconsumption of fructose","volume":"63","author":"Futatsugi","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2024.129930_b0085","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.medj.2021.04.007","article-title":"Inhibition of ketohexokinase in adults with NAFLD reduces liver fat and inflammatory markers: a randomized phase 2 trial","volume":"2","author":"Kazierad","year":"2021","journal-title":"Med"},{"issue":"n\/a","key":"10.1016\/j.bmcl.2024.129930_b0090","article-title":"A phase 2a, randomized, double-blind, placebo-controlled, 3-arm, parallel-group study to assess the efficacy, safety, tolerability, and pharmacodynamics of PF-06835919 in patients with nonalcoholic fatty liver disease and type 2 diabetes mellitus","volume":"n\/a","author":"Saxena","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.bmcl.2024.129930_b0095","unstructured":"Ketohexokinase Inhibition in NAFLD (KHKil). <https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05463575> [accessed February 4, 2023]."},{"key":"10.1016\/j.bmcl.2024.129930_b0100","unstructured":"Ketohexokinase Inhibition in Hereditary Fructose Intolerance (KHKi in HFI). <https:\/\/clinicaltrials.gov\/study\/NCT06089265> [accessed March 23, 2024, Published 2024]."},{"key":"10.1016\/j.bmcl.2024.129930_b0105","unstructured":"A Study of LY3522348 in Healthy Participants. <https:\/\/www.clinicaltrials.gov\/study\/NCT04559568?term=NCT04559568&rank=1> [accessed May 16, 2024, Published 20]."},{"key":"10.1016\/j.bmcl.2024.129930_b0110","unstructured":"A Study of LY3478045 in Healthy Particpants. <https:\/\/www.clinicaltrials.gov\/study\/NCT04270370?term=NCT04270370&rank=1> [accessed May 16, 2024, Published 2021]."},{"key":"10.1016\/j.bmcl.2024.129930_b0115","doi-asserted-by":"crossref","first-page":"15960","DOI":"10.1021\/acs.jmedchem.3c01410","article-title":"Identification of LY3522348: a highly selective and orally efficacious Ketohexokinase inhibitor","volume":"66","author":"Durham","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2024.129930_b0120","unstructured":"Durham TB, Hao J, Johnston RD, Inventors. 2-[2-methylazetidin-1-yl]-4-phenyl-6-(trifluoromethyl)-pyrimidine compounds. US patent WO2021162943A1; August 19, 2021."},{"key":"10.1016\/j.bmcl.2024.129930_b0125","unstructured":"Coates DA, Durham TB, Johnston RD, et al., Inventors. Disubstituted pyrazole compounds as ketohexokinase inhibitors. US patent WO2020257171A1. December 24; 2020."},{"key":"10.1016\/j.bmcl.2024.129930_b0130","doi-asserted-by":"crossref","first-page":"13501","DOI":"10.1021\/acs.jmedchem.3c00715","article-title":"Discovery of a novel Ketohexokinase inhibitor with improved drug distribution in target tissue for the treatment of fructose metabolic disease","volume":"66","author":"Zhu","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2024.129930_b0135","doi-asserted-by":"crossref","first-page":"4762","DOI":"10.1016\/j.bmcl.2011.06.067","article-title":"Optimization of a pyrazole hit from FBDD into a novel series of indazoles as ketohexokinase inhibitors","volume":"21","author":"Zhang","year":"2011","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmcl.2024.129930_b0140","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1021\/ml200070g","article-title":"Inhibitors of ketohexokinase: discovery of pyrimidinopyrimidines with specific substitution that complements the ATP-binding site","volume":"2","author":"Maryanoff","year":"2011","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmcl.2024.129930_b0145","doi-asserted-by":"crossref","first-page":"7979","DOI":"10.1021\/jm100677s","article-title":"Electron density guided fragment-based lead discovery of ketohexokinase inhibitors","volume":"53","author":"Gibbs","year":"2010","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2024.129930_b0150","doi-asserted-by":"crossref","first-page":"5326","DOI":"10.1016\/j.bmcl.2012.06.008","article-title":"Pyrimidinopyrimidine inhibitors of ketohexokinase: exploring the ring C2 group that interacts with Asp-27B in the ligand binding pocket","volume":"22","author":"Maryanoff","year":"2012","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmcl.2024.129930_b0155","doi-asserted-by":"crossref","first-page":"7835","DOI":"10.1021\/acs.jmedchem.7b00947","article-title":"Discovery of fragment-derived small molecules for in vivo inhibition of Ketohexokinase (KHK)","volume":"60","author":"Huard","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2024.129930_b0160","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1002\/cmdc.202000164","article-title":"Physicochemical properties of Zwitterionic drugs in therapy","volume":"15","author":"Maz\u00e1k","year":"2020","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bmcl.2024.129930_b0165","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.1021\/cr9601019","article-title":"Lipophilicity profiles of ampholytes","volume":"97","author":"Pagliara","year":"1997","journal-title":"Chem Rev"},{"key":"10.1016\/j.bmcl.2024.129930_b0170","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1016\/j.bbamem.2012.05.027","article-title":"Mechanism for translocation of fluoroquinolones across lipid membranes","volume":"1818","author":"Cramariuc","year":"2012","journal-title":"Biochim Biophys Acta Biomembr"},{"key":"10.1016\/j.bmcl.2024.129930_b0175","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.4155\/fmc-2016-0176","article-title":"Zwitterionic structures: from physicochemical properties toward computer-aided drug designs","volume":"8","author":"Yang","year":"2016","journal-title":"Future Med Chem"},{"key":"10.1016\/j.bmcl.2024.129930_b0180","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1021\/ci800272a","article-title":"Searching fragment spaces with feature trees","volume":"49","author":"Lessel","year":"2009","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.bmcl.2024.129930_b0185","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1023\/A:1008068904628","article-title":"Feature trees: a new molecular similarity measure based on tree matching","volume":"12","author":"Rarey","year":"1998","journal-title":"J Comput Aided Mol Des"},{"key":"10.1016\/j.bmcl.2024.129930_b0190","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1023\/A:1011144622059","article-title":"Similarity searching in large combinatorial chemistry spaces","volume":"15","author":"Rarey","year":"2001","journal-title":"J Comput Aid Mol Des"},{"key":"10.1016\/j.bmcl.2024.129930_b0195","unstructured":"CoLibri [computer program]. St. Augustine, FL: BioSolveIT."},{"key":"10.1016\/j.bmcl.2024.129930_b0200","unstructured":"Corina [computer program]. Version 3.46. Erlangen, Germany: Molecular Networks GmbH; 2008."},{"key":"10.1016\/j.bmcl.2024.129930_b0205","unstructured":"Omega [computer program]. Version 2.5.1.4. Santa Fe, NM: OpenEye Scientific Software."},{"key":"10.1016\/j.bmcl.2024.129930_b0210","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1021\/ci100031x","article-title":"Conformer generation with OMEGA: Algorithm and validation using high quality structures from the protein databank and cambridge structural database","volume":"50","author":"Hawkins","year":"2010","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.bmcl.2024.129930_b0215","unstructured":"ROCS [computer program]. Version 3.2.0.4. Santa Fe, NM: OpenEye Scientfic."},{"key":"10.1016\/j.bmcl.2024.129930_b0220","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1021\/jm0603365","article-title":"Comparison of shape-matching and docking as virtual screening tools","volume":"50","author":"Hawkins","year":"2007","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2024.129930_b0225","unstructured":"Molecular Operating Environment [computer program]. Montreal, QC: Chemical Computing Group."},{"key":"10.1016\/j.bmcl.2024.129930_b0230","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1107\/S2059798323006137","article-title":"Crystal structures of human and mouse ketohexokinase provide a structural basis for species- and isoform-selective inhibitor design","volume":"79","author":"Ebenhoch","year":"2023","journal-title":"Acta Crystallogr Sect D"},{"key":"10.1016\/j.bmcl.2024.129930_b0235","first-page":"114","article-title":"Laws governing the dissociation of dialkylphosphoric, -phosphonic and -phosphinic acids in water and in aqueous ethanol","volume":"318","author":"Galkin","year":"1991","journal-title":"Dokl Chem"},{"key":"10.1016\/j.bmcl.2024.129930_b0240","doi-asserted-by":"crossref","first-page":"9856","DOI":"10.1021\/acs.jmedchem.0c01020","article-title":"Discovery and optimization of novel SUCNR1 inhibitors: Design of Zwitterionic derivatives with a salt bridge for the improvement of oral exposure","volume":"63","author":"Velcicky","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2024.129930_b0245","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.1021\/acs.jmedchem.8b00347","article-title":"Impact of dynamically exposed polarity on permeability and solubility of chameleonic drugs beyond the rule of 5","volume":"61","author":"Rossi Sebastiano","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2024.129930_b0250","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/d41573-022-00071-9","article-title":"opnMe.com: a digital initiative for sharing tools with the biomedical research community","volume":"21","author":"Gollner","year":"2022","journal-title":"Nat Rev Drug Discov"}],"container-title":["Bioorganic &amp; Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X24003329?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X24003329?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,14]],"date-time":"2024-09-14T21:43:12Z","timestamp":1726350192000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X24003329"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":50,"alternative-id":["S0960894X24003329"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2024.129930","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of BI-9787, a potent zwitterionic ketohexokinase inhibitor with oral bioavailability","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2024.129930","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"129930"}}